Clik here to view.
Pear Therapeutics closes $64m Series C round
Pear Therapeutics said this month that it closed a $64 million Series C round led by Temasek. The Boston-based company plans to use its newly-acquired funds to support the global commercialization of...
View ArticleClik here to view.
Reva brings bioresorbable scaffolds to new markets
Reva Medical (ASX:RVA) said this week that it inked four new distribution agreements, bringing its commercial operations to seven European countries. The San Diego, Calif.-based company said the deals...
View ArticleClik here to view.
Propeller Health launches in-app pharmacy feature
Propeller Health today launched a feature within the Propeller mobile app designed to connect users directly with pharmacy services. The Madison, Wis.-based company kicked off the feature with...
View ArticleClik here to view.
Beta Bionics raises $63m for bionic pancreas
Boston-based Beta Bionics said this week that it closed a $63 million Series B round to support the development of its iLet bionic pancreas system for people with Type 1 diabetes. The company’s iLet...
View ArticleClik here to view.
Ocular Therapeutix seeks second indication for drug-delivery eye insert
Ocular Therapeutix (NSDQ:OCUL) said yesterday that it submitted a supplement NDA to the FDA for its dexamethasone ocular insert, Dextenza. The Bedford, Mass.-based company requested that the U.S....
View ArticleClik here to view.
Valeritas’ V-Go nabs preferred status on OptumRx formularies
Valeritas (NSDQ:VLRX) said today that its wearable insulin delivery device, V-Go, won preferred status on the OptumRx formulary. The Bridgewater, N.J.-based company’s device is designed for people with...
View ArticleClik here to view.
Amneal wins FDA nod for generic rivastigmine transdermal patch
Amneal Pharmaceuticals (NYSE:AMRX) said today that it won FDA approval for a generic rivastigmine transdermal patch. The drug, which is sold under the brand name Exelon, is an acetylcholinesterase...
View ArticleClik here to view.
Pharma stocks fall as Rep. Cummings launches drug pricing investigation
Chairman of the House Oversight Committee Rep. Elijah Cummings (D-MD) launched an investigation today into the drug pricing practices of 12 pharmaceutical companies. A number of companies named in the...
View ArticleClik here to view.
What’s ahead for the drug delivery market in 2019?
Cindy Reiss-Clark, VP & GM of West‘s (NYSE:WST) global biologics business, comments on the drug delivery trends that stood out from 2018 and what she’s keeping an eye on in the coming year. What...
View ArticleClik here to view.
Researchers question use of antibiotic shunts in hydrocephalus patients
Led by neurosurgeon Dr. Benjamin Warf, a team of researchers from Boston Children’s Hospital published a study this month questioning the benefits of using shunts impregnated with antibiotics to treat...
View ArticleClik here to view.
Rep. Cummings talks drug pricing with HHS chief
Days after unveiling an investigation into the drug pricing practices of 12 pharmaceutical companies, House Oversight Committee Chairman Rep. Elijah Cummings (D-Md.) met with the Secretary of Health...
View ArticleClik here to view.
QT Vascular expands pivotal trial of Chocolate Touch DCB
QT Vascular said today that the FDA approved the company’s request to expand an on-going pivotal study of its Chocolate Touch drug-coated balloon to include the use of atherectomy for lesion...
View ArticleClik here to view.
Proteus debuts digital cancer drug
Proteus Digital Health said today that the first cancer patients were treated using its digital oncology therapy, which combines oral chemotherapy with an ingestible sensor. Patients with stage 3 and 4...
View ArticleClik here to view.
Medtronic kicks off study for pain pump
Medtronic (NYSE:MDT) said today that it enrolled the first patient in a study to assess the use of its SynchroMed II intrathecal drug delivery system as an alternative to oral opioids. The 100-patient...
View ArticleClik here to view.
Sandoz launches PFS alternative to epinephrine auto-injector
Novartis (NYSE:NVS) division Sandoz said today that it launched its Symjepi epinephrine pre-filled syringe in the U.S. The company’s product is designed as an alternative to epinephrine auto-injectors...
View ArticleClik here to view.
Johnson & Johnson, Apple ink collab for AFib study
Johnson & Johnson‘s (NYSE:JNJ) Janssen and Apple (NSDQ:AAPL) said today that the two companies inked a deal to study if an app from J&J in combination with the Apple Watch’s ECG app and...
View ArticleClik here to view.
Windgap Medical raises $12m for epinephrine auto-injector
Windgap Medical has raised $12 million from 106 investors as part of a $27 million round, according to a document filed with the SEC. The Watertown, Mass.-based company is developing an epinephrine...
View ArticleClik here to view.
FDA probes paclitaxel-eluting stents, balloons
The FDA wrote a letter to healthcare providers yesterday on the heels of a meta-analysis that suggested an increased mortality rate after two years in people with peripheral artery disease who were...
View ArticleClik here to view.
FDA takes big step toward over-the-counter naloxone
Image Credit: NIDA In a first for the agency, the FDA has developed and tested a consumer-friendly Drug Facts label to support the development of an over-the-counter version of naloxone, an emergency...
View ArticleClik here to view.
LINC 2019: Medtronic, Boston Scientific back paclitaxel devices amid safety...
Amid concerns about a potential link between paclitaxel devices and heightened long-term mortality rates, Medtronic (NYSE:MDT) and other device-makers doubled down on their products’ safety at this...
View Article